Clinical Data Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off BioSpaceSanofi has faced questions about the potential of lunsekimig in eczema, with executives calling the clinical trial a "measured risk."Clinical DataImmunology & InflammationRead full story pharminent April 7, 2026 (Last updated: April 7, 2026) BioSpace Sanofi has faced questions about the potential of lunsekimig in eczema, with executives calling the clinical trial a “measured risk.” Clinical DataImmunology & InflammationRead full story Post navigation Previous: Sanofi immune drug hopeful posts mixed results in mid-stage testsNext: In the face of tariffs, FDA-approved drug manufacturing deals are shifting to Europe Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
